Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 5/20 | 0.44 |
| ▸ | PPARA | Q07869 | 4/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6380461 | 0.89 | MTNR1A (0.50) | MTNR1AMTNR1BLDHAPPARGPPARA | |
| SCHEMBL7073559 | 0.85 | PDE4B (0.48) | MTNR1AMTNR1BLDHAPPARGPPARA | |
| SCHEMBL7080523 | 0.83 | PPARG (0.44) | PPARGPPARAALOX5SLC6A3CHRM1 | |
| SCHEMBL7075493 | 0.82 | ALDH1A1 (0.43) | MTNR1AMTNR1BLDHAPPARGPPARA | |
| SCHEMBL7078743 | 0.81 | GRIK1 (0.48) | PPARGPPARAALOX5TDP1NPC1 | |
| SCHEMBL6377276 | 0.80 | PLA2G4B (0.41) | MTNR1AMTNR1BLDHAPPARGPPARA | |
| SCHEMBL7074193 | 0.80 | PPARG (0.56) | LDHAPPARGPPARATDP1 | |
| SCHEMBL6378034 | 0.79 | HTT (0.51) | MTNR1AMTNR1BALDH1A1CA1CA2 | |
| SCHEMBL7077459 | 0.79 | MEN1 (0.46) | NPC1TP53ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL12264723 | 0.78 | MMP2 (0.49) | MTNR1AMTNR1BLDHAPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | OWEN DAVID ALAN (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6566384-B1 | For therapy of cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response | DARWIN DISCOVERY LTD. (GB) | 2003-05-20 | — | — | US | disclosed |
| US-6118001-A | ANTICANCER AGENT; ANTIARTHRITIC AGENT | DARWIN DISCOVERY, LTD. (GB) | 2000-09-12 | — | — | US | disclosed |
| EP-0968182-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998005635-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | MMP13, MMP2, MMP9 | TAS1R3 3715/4885TAS1R1 3500/4885MTNR1A 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.